🇺🇸 Selective serotonin re-uptake inhibitor in United States
7 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 7
Most-reported reactions
- Deafness Neurosensory — 1 report (14.29%)
- Labyrinthitis — 1 report (14.29%)
- Nystagmus — 1 report (14.29%)
- Tinnitus — 1 report (14.29%)
- Tympanic Membrane Disorder — 1 report (14.29%)
- Vertigo — 1 report (14.29%)
- Vomiting — 1 report (14.29%)
Other Psychiatry / Neurology approved in United States
Frequently asked questions
Is Selective serotonin re-uptake inhibitor approved in United States?
Selective serotonin re-uptake inhibitor does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Selective serotonin re-uptake inhibitor in United States?
New Valley University is the originator. The local marketing authorisation holder may differ — check the official source linked above.